Publications by authors named "W A Kampman"
Importance: The monoclonal antibody combination of casirivimab and imdevimab reduced viral load, hospitalization, or death when administered as a 1200-mg or greater intravenous (IV) dose in a phase 3 COVID-19 outpatient study. Subcutaneous (SC) and/or lower IV doses should increase accessibility and/or drug supplies for patients.
Objective: To assess the virologic efficacy of casirivimab and imdevimab across different IV and SC doses compared with placebo.
Background: Open-label platform trials and a prospective meta-analysis suggest efficacy of anti-interleukin (IL)-6R therapies in hospitalized patients with coronavirus disease 2019 (COVID-19) receiving corticosteroids. This study evaluated the efficacy and safety of sarilumab, an anti-IL-6R monoclonal antibody, in the treatment of hospitalized patients with COVID-19.
Methods: In this adaptive, phase 2/3, randomized, double-blind, placebo-controlled trial, adults hospitalized with COVID-19 received intravenous sarilumab 400 mg or placebo.
Background: Patients with immunodeficiency-associated antibody disorders are at a higher risk of prolonged/persistent COVID-19 infection, having no viable treatment options.
Methods: A retrospective analysis of patients with primary and/or secondary immunodeficiency-associated antibody disorders who received casirivimab and imdevimab (REGEN-COV®) under emergency compassionate use. Objective were to describe safety and response to REGEN-COV, focusing on the subset of patients who had COVID-19 duration ≥21 days before treatment.
Article Synopsis
- In the REGEN-COV adaptive trial, a combination of monoclonal antibodies significantly reduced both viral load and hospital visits in COVID-19 patients compared to a placebo.
- In the phase 3 trial, outpatients with COVID-19 received either REGEN-COV or placebo, leading to a substantial decrease in hospitalization or death rates (1.3% in the 2400-mg group vs. 4.6% in placebo).
- The treatment also expedited symptom resolution by an average of 4 days and effectively reduced viral load more rapidly than the placebo across various patient subgroups.
Background: Non-statin lipid lowering therapies (LLTs) provide additional treatment options for patients. Use patterns and patient perceptions of non-statin LLT remain incompletely described.
Hypothesis: The guideline-recommended statin intensity remains underutilized in patients treated with and without non-statin LLT.